DE60031951D1 - Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen - Google Patents

Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen

Info

Publication number
DE60031951D1
DE60031951D1 DE60031951T DE60031951T DE60031951D1 DE 60031951 D1 DE60031951 D1 DE 60031951D1 DE 60031951 T DE60031951 T DE 60031951T DE 60031951 T DE60031951 T DE 60031951T DE 60031951 D1 DE60031951 D1 DE 60031951D1
Authority
DE
Germany
Prior art keywords
methods
gastrointestinal
disorders
neurotrophine
hypomobility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60031951T
Other languages
German (de)
English (en)
Inventor
M Cedarbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Application granted granted Critical
Publication of DE60031951D1 publication Critical patent/DE60031951D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
DE60031951T 1999-01-15 2000-01-11 Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen Expired - Lifetime DE60031951D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/232,171 US6656474B1 (en) 1999-01-15 1999-01-15 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
PCT/US2000/000682 WO2000041719A1 (en) 1999-01-15 2000-01-11 Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders

Publications (1)

Publication Number Publication Date
DE60031951D1 true DE60031951D1 (de) 2007-01-04

Family

ID=22872143

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60031951T Expired - Lifetime DE60031951D1 (de) 1999-01-15 2000-01-11 Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen

Country Status (13)

Country Link
US (1) US6656474B1 (enExample)
EP (1) EP1146899B1 (enExample)
JP (1) JP4489303B2 (enExample)
AT (1) ATE345811T1 (enExample)
AU (1) AU775860B2 (enExample)
CA (1) CA2360252C (enExample)
DE (1) DE60031951D1 (enExample)
IL (2) IL144315A0 (enExample)
NO (1) NO329488B1 (enExample)
NZ (1) NZ512968A (enExample)
TR (2) TR200102767T2 (enExample)
WO (1) WO2000041719A1 (enExample)
ZA (1) ZA200105799B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02012602A (es) * 2000-06-22 2003-05-14 Genentech Inc Anticuerpos monoclonales agonistas anti-trk-c.
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
JP2006520806A (ja) * 2003-03-20 2006-09-14 ライナット ニューロサイエンス コーポレイション タキソール誘導性腸障害を処置する方法
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US20100094560A1 (en) * 2006-08-15 2010-04-15 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
CA2807036C (en) 2010-10-14 2018-01-16 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
AU2014301631A1 (en) 2013-06-26 2015-08-27 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987136A (en) * 1982-03-16 1991-01-22 The Rockefeller University Method for controlling gastrointestinal dysmotility
US5962404A (en) * 1989-08-28 1999-10-05 Yeda Research & Development Co., Ltd. Enzymatically-produced oligodendrocyte cytotoxic dimeric IL-2 factor
US6174701B1 (en) * 1989-12-12 2001-01-16 Genentech, Inc. Neuronal factor
AU4920893A (en) * 1992-09-14 1994-04-12 Regeneron Pharmaceuticals, Inc. Method of producing analgesia using neurotrophins
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
CA2188017C (en) * 1994-04-25 2010-09-28 Joffre Baker Cardiotrophin and uses therefor
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6211142B1 (en) 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5616724A (en) * 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
JP3540912B2 (ja) * 1997-03-28 2004-07-07 京セラ株式会社 釣糸用ガイド部材
WO1998049308A1 (en) 1997-04-25 1998-11-05 Genentech, Inc. Ngf variants
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor

Also Published As

Publication number Publication date
NZ512968A (en) 2003-09-26
TR200201875T2 (tr) 2002-09-23
NO20013493D0 (no) 2001-07-13
CA2360252C (en) 2010-11-02
ZA200105799B (en) 2002-01-24
CA2360252A1 (en) 2000-07-20
IL144315A (en) 2008-08-07
NO20013493L (no) 2001-09-17
IL144315A0 (en) 2002-05-23
JP4489303B2 (ja) 2010-06-23
EP1146899A1 (en) 2001-10-24
JP2002534479A (ja) 2002-10-15
AU2963600A (en) 2000-08-01
TR200102767T2 (tr) 2002-04-22
EP1146899B1 (en) 2006-11-22
EP1146899A4 (en) 2003-03-05
ATE345811T1 (de) 2006-12-15
NO329488B1 (no) 2010-10-25
AU775860B2 (en) 2004-08-19
US6656474B1 (en) 2003-12-02
WO2000041719A9 (en) 2001-08-30
WO2000041719A1 (en) 2000-07-20

Similar Documents

Publication Publication Date Title
DE60031951D1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE60015070D1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DE60120667D1 (de) Methoden und mittel zur behandlung von bandscheibenverschleiss
EP1324780A4 (en) METHODS OF TREATING CARDIAC ARRHYTHMIA
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
DE69813898D1 (de) Substituierte porphyrinen
DE69931377D1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
DE60142839D1 (de) Botulinum Toxin zur Behandlung von akuten Verletzungen der Skelettmuskeln
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE526041T1 (de) Verfahren zur hemmung okularer vorgänge
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
DE60222745D1 (de) Verwendung von neurofilamentproteinen zur behandlung von tumoren
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
DE69915690D1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
DE69818809D1 (de) Verfahren zur behandlung von narbengewebe
DE69923559D1 (de) Methoden zur inhibierung von helicobacter pylori
ATE409732T1 (de) Methoden zur vorbehandlung von schuhen
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
ATE258064T1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
SE0003126D0 (sv) Method of treatment
DE50210718D1 (de) Verfahren zur behandlung von schlamm

Legal Events

Date Code Title Description
8332 No legal effect for de